Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 311-326

  Lee, Cheng Hung ^a,b   Lin, Yu Huang ^c   Chang, Shang Hung ^a   Tai, Chun Der ^c   Liu, Shih Jung ^b   Chu, Yen ^d   Wang, Chao Jan ^b   Hsu, Ming Yi ^b   Chang, Hung ^e   Chang, Gwo Jyh ^a   Hung, Kuo Chun ^a   Hsieh, Ming Jer ^a   Lin, Fen Chiung ^a   Hsieh, I Chang ^a   Wen, Ming Shien ^a   Huang, Yenlin ^e  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b Department of Mechanical Engineering ^*  (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d Laboratory of Cardiovascular Physiology   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acetylsalicylic acid; Biodegradable drug eluting nanofibers; Cell adhesion to vascular stents; Release characteristics

Indexed keywords

ACETYLSALICYLIC ACID; BIODEGRADABLE DRUG ELUTING NANOFIBER; COLLAGEN TYPE 1; HEXAFLUORO 2 PROPANOL; NANOFIBER; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; DRUG RELEASE; ELECTROSPINNING; ELUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOGENESIS; HISTOPATHOLOGY; HYBRID STENT; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ADHERENCE; MALE; MONOCYTE; NANOFABRICATION; NONHUMAN; RABBIT; REENDOTHELIALIZATION; SCANNING ELECTRON MICROSCOPY; STENT THROMBOSIS; THROMBOCYTE ADHESION; THROMBOGENICITY; TISSUE REACTION; TREATMENT DURATION; VASCULAR STENT;

ACETYLSALICYLIC ACID; BIODEGRADABLE DRUG-ELUTING NANOFIBERS; CELL ADHESION TO VASCULAR STENTS; RELEASE CHARACTERISTICS;

ABSORBABLE IMPLANTS; ANIMALS; ASPIRIN; BLOOD VESSEL PROSTHESIS; CELL ADHESION; DRUG IMPLANTS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; NANOFIBERS; NEOVASCULARIZATION, PHYSIOLOGIC; PARTICLE SIZE; PLATELET ADHESIVENESS; RABBITS; STENTS; TREATMENT OUTCOME;

EID: 84891814014     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51258     Document Type: Article

References (55)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188-197.
2. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52(5):333-342.
3. Cook S, Windecker S. Early stent thrombosis: past, present, and future. Circulation. 2009;119(5):657-659.
4. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-e157.
5. Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol. 2002;40(9):1567-1572.
6. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 1998;98(2):104-111.
7. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316(12):701-706.
8. Kimura T, Morimoto T, Kozuma K, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010;122(1):52-61.
9. Aoki J, Lansky AJ, Mehran R, et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2009;119(5):687-698.
10. Kiefer TL, Becker RC. Inhibitors of platelet adhesion. Circulation. 2009;120(24):2488-2495.
11. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101(9):948-954.
12. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol. 1985;5(Suppl 6):175B-184B.
13. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood. 1994;83(4):885-898.
14. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation. 2002;105(22):2600-2604.
15. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
16. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke. 2005;36(2):276-280.
17. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation. 1997;95(1):63-68.
18. Altman R, Scazziota A. Why aspirin cannot prevent arterial thrombosis. Circulation. 1996;94(11):3002-3003.
19. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part I. Circulation. 2002;106(21):2734-2740.
20. Lu F, Shen YY, Shen YQ, Hou JW, Wang ZM, Guo SR. Treatments of paclitaxel with poly(vinyl pyrrolidone) to improve drug release from poly(varepsilon-caprolactone) matrix for film-based stent. Int J Pharm. 2012;434(1-2):161-168.
21. Teo WE, Ramakrishna S. A review on electrospinning design and nanofibre assemblies. Nanotechnology. 2006;17(14):R89-R106.
22. Nakazawa G, Granada JF, Alviar CL, et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv. 2010;3(1):68-75.
23. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31(1):224-230.
24. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19(2):267-274.
25. Ramchandani M, Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J Control Release. 1998;54(2):167-175.
26. Amann LC, Gandal MJ, Lin R, Liang Y, Siegel SJ. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Pharm Res. 2010;27(8):1730-1737.
27. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311(19):1206-1211.
28. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56(3):624-632.
29. Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention. 2009;5 Suppl, F58-F64.
30. Shekhonin BV, Domogatsky SP, Muzykantov VR, Idelson GL, Rukosuev VS. Distribution of type I, III, IV and V collagen in normal and atherosclerotic human arterial wall: immunomorphological characteristics. Coll Relat Res. 1985;5(4):355-368.
31. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation. 1992;86(3):723-729.
32. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol. 1996;28(2): 345-353.
33. Beekhuizen H, van Furth R. Monocyte adherence to human vascular endothelium. J Leukoc Biol. 1993;54(4):363-378.
34. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program. 2011;2011:51-61.
35. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol. 2009;103(Suppl 3):4A-10A.
36. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8):1051-1058.
37. Montalescot G, Maclouf J, Drobinski G, Salloum J, Grosgogeat Y, Thomas D. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Coll Cardiol. 1994;24(1):33-38.
38. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995;91(7):1914-1917.
39. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-782.
40. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49(12):1362-1368.
41. Miyauchi K, Kasai T, Yokayama T, et al. Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circ J. 2008;72(5):832-838.
42. Kong JY, Wang TQ, Jiang GH, Li L, Wang FP. Urinary trypsin inhibitor reduced inflammatory response after stent injury in minipig. Pathol Res Pract. 2012;208(6):344-349.
43. Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol. 2000;36(3):699-705.
44. Finkelstein A, McClean D, Kar S, et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation. 2003;107(5):777-784.
45. Mazur W, Grinstead WC, Hakim AH, et al. Fate of side branches after intracoronary implantation of the Gianturco-Roubin flex-stent for acute or threatened closure after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1994;74(12):1207-1210.
46. Xu J, Hahn JY, Song YB, et al. Carina shift versus plaque shift for aggravation of side branch ostial stenosis in bifurcation lesions: volumetric intravascular ultrasound analysis of both branches. Circ Cardiovasc Interv. 2012;5(5):657-662.
47. Toyofuku M, Kimura T, Morimoto T, et al. Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry. Circulation. 2009;120(19):1866-1874.
48. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33(10):1214-1222.
49. Wessely R. New drug-eluting stent concepts. Nat Rev Cardiol. 2010;7(4):194-203.
50. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009;30(20):2441-2449.
51. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372(9644):1163-1173.
52. Lu L, Peter SJ, Lyman MD, et al. In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams. Biomaterials. 2000;21(18):1837-1845.
53. Kumbar SG, Nukavarapu SP, James R, Nair LS, Laurencin CT. Electrospun poly(lactic acid-co-glycolic acid) scaffolds for skin tissue engineering. Biomaterials. 2008;29(30):4100-4107.
54. Ali SA, Doherty PJ, Williams DF. Mechanisms of polymer degradation in implantable devices. 2. Poly(DL-lactic acid). J Biomed Mater Res. 1993;27(11):1409-1418.
55. Powell HM, Supp DM, Boyce ST. Influence of electrospun collagen on wound contraction of engineered skin substitutes. Biomaterials. 2008;29(7):834-843.